Selective RET Inhibition in Metastatic RET-Mutant Medullary Thyroid Cancer and RET Fusion–Positive Differentiated Thyroid Cancer

Gain expert insight on managing NTRK- and RET-altered malignancies and optimal methods for detecting gene fusions, in this webcast from Clinical Care Options (CCO)

Alexander Drilon, MD
Program Director Thomas Stinchcombe, MD
Program Director Saad A. Khan, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit™ Registered Nurses: 1.0 Nursing contact hour Pharmacists: 1.0 contact hour (0.1 CEUs) Released: June 10, 2022 Expired: June 9, 2023

Dr Evan J. Lipson shares expert insights on the safety and efficacy of anti-LAG-3 immunotherapies in this webcast from Clinical Care Options (CCO)

Evan J. Lipson, MD Tian Zhang, MD, MHS Physicians: maximum of 0.75 AMA PRA Category 1 Credits™ Registered Nurses: 0.75 Nursing contact hours Pharmacists: 0.75 contact hours (0.075 CEUs) Released: April 20, 2022 Expired: April 19, 2023

Downloadable slideset from a workshop series from Clinical Care Options (CCO) on the management of NTRK and RET-altered malignancies.

Alexander Drilon, MD Thomas Stinchcombe, MD Released: April 12, 2022

Downloadable PDF resource on LAG-3, safety and efficacy of approved anti-LAG-3 agent relatlimab, and clinical trial spotlight from Clinical Care Options (CCO)

Krista M. Rubin, MS, RN, FNP-BC Released: March 23, 2022